WIN027 / Qyuns Therap, Windward Bio - LARVOL DELTA

A multicentre, randomised, double-blind, single- and multiple-dose escalation, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic profile, pharmacodynamic effects, and immunogenicity of QX027N in healthy subjects and patients with moderate-to-severe atopic dermatitis. (ChiCTR) - P1 | N=65 | Not yet recruiting | Sponsor: Hangzhou First People's Hospital; Qyuns Therapeutics Co., Ltd.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatology (GlobeNewswire) - "Under the terms of the agreement, Windward Bio will gain exclusive rights to develop, manufacture, and commercialize WIN027 outside of China. Total deal value is up to $700M, including upfront payment, equity, and milestones that may be paid to Qyuns Therapeutics, contingent upon the achievement of specific development, regulatory, and commercial milestones, as well as tiered royalties on product sales."

Licensing / partnership • Asthma • Dermatology • Immunology

LONG-ACTING BISPECIFIC ANTIBODY QX027N OBTAINS TWO CLINICAL TRIAL APPROVALS (HKEXnews) - "...Approvals from the Center for Drug Evaluation of the National Medical Products Administration (Acceptance Nos.: CXSL2500757, CXSL2500758), intended for the treatment of asthma and atopic dermatitis."

New trial • Asthma • Atopic Dermatitis • Immunology